etoposide has been researched along with strontium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, XL; Liu, H; Qian, WY; Sun, DM; Wang, SL; Zhu, RR | 1 |
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
1 review(s) available for etoposide and strontium
| Article | Year |
|---|---|
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
1 other study(ies) available for etoposide and strontium
| Article | Year |
|---|---|
pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carbonates; Delayed-Action Preparations; Etoposide; Humans; Hydrogen-Ion Concentration; Nanocapsules; Neoplasms, Experimental; Particle Size; Strontium; Treatment Outcome | 2012 |